Cell-Free DNA: Potential Application in COVID-19 Diagnostics and Management.
Robert StawskiDariusz NowakEwelina PerdasPublished in: Viruses (2022)
WHO has declared COVID-19 as a worldwide, public health emergency. The elderly, pregnant women, and people with associated co-morbidities, including pulmonary disease, heart failure, diabetes, and cancer are the most predisposed population groups to infection. Cell-free DNA is a very commonly applied marker, which is elevated in various pathological conditions. However, it has a much higher sensitivity than standard biochemical markers. cfDNA appears to be an effective marker of COVID-19 complications, and also serves as a marker of certain underlying health conditions and risk factors of severe illness during COVID-19 infection. We aimed to present the possible mechanisms and sources of cfDNA released during moderate and severe infections. Moreover, we attempt to verify how efficiently cfDNA increase could be applied in COVID-19 risk assessment and how it corresponds with epidemiological data.
Keyphrases
- coronavirus disease
- public health
- sars cov
- heart failure
- risk factors
- pregnant women
- risk assessment
- healthcare
- human health
- respiratory syndrome coronavirus
- early onset
- cardiovascular disease
- squamous cell carcinoma
- left ventricular
- machine learning
- metabolic syndrome
- papillary thyroid
- skeletal muscle
- atrial fibrillation
- big data
- climate change
- artificial intelligence
- weight loss
- insulin resistance
- lymph node metastasis
- childhood cancer